Balance Sheet Information (Tables)
|
9 Months Ended |
Sep. 30, 2023 |
|---|
| Balance Sheet Related Disclosures [Abstract] |
|
| Schedule of cash and cash equivalents and restricted cash |
A summary of cash and cash equivalents and restricted cash is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2023 |
|
December 31, 2022 |
| Cash and Cash Equivalents |
$ |
5,400,498 |
|
|
$ |
5,964,556 |
|
| Restricted Cash, Non-current |
4,031 |
|
|
49,260 |
|
| Total Cash, Cash Equivalents and Restricted Cash |
$ |
5,404,529 |
|
|
$ |
6,013,816 |
|
|
| Schedule of restricted cash |
A summary of cash and cash equivalents and restricted cash is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2023 |
|
December 31, 2022 |
| Cash and Cash Equivalents |
$ |
5,400,498 |
|
|
$ |
5,964,556 |
|
| Restricted Cash, Non-current |
4,031 |
|
|
49,260 |
|
| Total Cash, Cash Equivalents and Restricted Cash |
$ |
5,404,529 |
|
|
$ |
6,013,816 |
|
|
| Schedule of prepaid expenses and other current assets |
Prepaid expenses and other current assets consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2023 |
|
December 31, 2022 |
| Prepaid Insurance |
$ |
116,853 |
|
|
$ |
117,315 |
|
| Prepaid Research and Development |
49,377 |
|
|
128,429 |
|
| Other |
73,161 |
|
|
97,325 |
|
| Total Prepaid Expenses and Other Current Assets |
$ |
239,391 |
|
|
$ |
343,069 |
|
|
| Schedule of accrued expenses |
Accrued expenses consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2023 |
|
December 31, 2022 |
| Payroll and Benefits |
$ |
828,694 |
|
|
$ |
1,312,443 |
|
| Professional Fees |
68,819 |
|
|
282,721 |
|
| Clinical Trials |
424,026 |
|
|
57,020 |
|
| Other |
140,172 |
|
|
183,750 |
|
| Total Accrued Expenses |
$ |
1,461,711 |
|
|
$ |
1,835,934 |
|
|